#GlobalBiosimilarsWeek is here! Each day, #biosimilars provide essential care for millions of people around the globe. In order to provide more patients with care, we need policies that support greater access to biosimilar medicines. Learn more: globalbiosimilarsweek.org

Join us as patients, healthcare providers, regulators and industry professionals discuss ways of “Advancing Access to Biosimilars” during #GlobalBiosimilarsWeek, with @IGBAmedicines Learn more about the event: globalbiosimilarsweek.org

#Biosimilars play a vital role in widening patient access to treatments. Find out how our member @Celltrioninc is #RewritingCancer.

We were pleased to be part of the expert reference group for the #Darzi review. The report is detailed but we believe the Government and NHS have an opportunity to widen patient access while saving money. Read the statement from our CEO @MarkSamuelsUK: bit.ly/3AYaJ9f

Congratulations to @karinsmyth, Baroness Gillian Merron and Lord Patrick Vallance on your appointments within the @DHSCgovuk Generic and biosimilar medicines play a vital part in sustaining the NHS and widening patient access. We look forward to working with you all.

Billions of pounds in #NHS savings could be in jeopardy unless biosimilar uptake is better supported. With a dedicated NHS #biosimilar strategy, the incoming Government could lock in £7 billion in NHS savings. Read our recommendations:

We are very pleased to announce the election of a new Vice-Chair for the BGMA - Paul Burden, UK Vice President Rx for STADA Thornton & Ross. Paul brings 25 years' experience in the off-patent sector, having been involved with the BGMA since 2011: britishgenerics.co.uk/view-news/paul…

Our May medicine supply issues dashboard shows historically high levels of generic discontinuations but overall the number of supply issues has reduced slightly to levels last seen in summer 2023. View the dashboard, based on NHS/DHSC data: britishgenerics.co.uk/view-news/bgma… #medicines

In our 2024 manifesto, we lay out workable solutions to support off-patent sector growth and restore the UK’s reputation as a key supply destination. This will in turn help increase NHS savings, expand patient access to treatment and alleviate shortages: britishgenerics.co.uk/view-news/bgma…

What are the challenges to and opportunities for greater #sustainability in the generic pharmaceutical industry? Hear from BGMA Sustainability and Partnerships Director, Michael Clarke, at the Manufacturing & Supply Chain Conference (@NationalMSC): eventbrite.ie/e/national-man…

Over 2 billion people lack access to healthcare globally. @ihp_uk play a vital role in getting medicines to disaster-hit and vulnerable communities. Watch their video and consider donating to the #BridgingtheGap Fund while donations are being matched: justgiving.com/campaign/ihpbr…

What’s at stake for the #NHS from the policies of an incoming Government? Well, £18bn in potential NHS savings from medicines due to come off patent over the next five years - that could be realised with a proactive, supportive policy environment. bit.ly/3PCKGJf

A new report from @NuffieldTrust highlights the 'new normal' of medicines shortages, offering key policy recommendations, including mutual recognition of batch testing between the EU and UK - something we have also long made a case for at the BGMA: nuffieldtrust.org.uk/research/the-f…

#BiosimilarMedicines policies are key contributors to maximising value in health, positively impacting patient access and healthcare systems globally. #BIOS24 starts today with lots of information on the value biosimilar medicines bring to both patients and healthcare systems.

We are pleased to support the Government's efforts to secure the UK's supplies of critical goods, with the launch of the #CriticalImportsCouncil - and welcome our inclusion as the sector that supplies 4 out of 5 prescription drugs the NHS uses: gov.uk/government/new…

Over 20 years, donations of unused generic medicines have helped millions of people globally, in regions like Ukraine, Malawi and Haiti. Find out more about supporting @ihp_uk’s #BridgingTheGap campaign, while donations are being matched: justgiving.com/campaign/ihpbr…

Future trade deals must protect the careful balance in the UK intellectual property framework between rewarding innovation and enabling fair competition that keeps medicines affordable for NHS patients. Further detail in our Manifesto: bit.ly/3PCKGJf #Trade

Yesterday @ihp_uk launched its #BridgingtheGap Fund – a new big push to ensure people in disaster-hit and vulnerable communities can access vital medicines. With more funds, IHP will be able to more rapidly respond to crises and support affected communities long term, despite…

The #BIOS24 Conference brings together healthcare leaders and experts to discuss how #biosimilarmedicines policies contribute to maximising value in health. Explore the latest developments and trends in biosimilar medicines in Amsterdam on 18-19 April: medicinesforeurope.com/events/bios24/

In the face of continual #medicineshortages, fresh policy thinking is needed to restore UK medicines supply chain resilience. A new fast-track license for products in shortage, for example, could help alleviate pressure. More detail in the Manifesto: bit.ly/3PCKGJf